With the increased liquidity in the biopharma sector and the changes resulting from tax reform, biopharma M&A is red hot. Evidence of this is clear globally as well as right here in the Boston area with several notable deals as of late.
While all this activity means lots of exciting deal-making on the buy-side, what does it mean for companies and, in particular, the BD/Finance professionals on the receiving end. We’ll ask our panel of BD/Finance leaders who have recently lived through the experience to share their perspectives. A few of the topics will include:
- When is the right time in your deal-making process to confront rumors that a change in ownership may be coming?
- What to say to prospective partners when a deal is announced?
- How does one continue to advance a late-stage deal under the shadow of a company sale?
- Is it possible to negotiate the conclusion of a deal as part of an acquisition discussion?
- How does the context of a possible merger or acquisition affect the nature of a deal and the terms being discussed?
- On the partner side, how does it change your interest in pursuing the closure of the deal?
- How can the experience of being acquired be turned around to benefit your career as a BD or Finance professional?
Date: July 30, 2018
Source: MassBio
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
